Company news

Genmab A/S news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

October 14, 2025

EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction

September 30, 2025

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

September 29, 2025

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

September 3, 2025

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 26, 2025

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

August 19, 2025

Genmab Announces Financial Results for the First Half of 2025

August 7, 2025

iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments

July 24, 2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

July 16, 2025

Genmab Announces Changes to its Executive Committee

July 1, 2025

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

June 15, 2025

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

June 2, 2025

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

May 27, 2025

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

May 21, 2025

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

May 14, 2025

Genmab Announces Financial Results for the First Quarter of 2024

May 8, 2025

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

May 1, 2025

← Newer news releases

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 21 decks. Every deck is listed under its year.